All In Biotech

Drug Trial Radar · NCT05790304

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

A Phase I, Single Dose, Non-Randomised, Multicentre, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Camizestrant in Post Menopausal Female Subjects

Last checked: Nov 20, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Feb 20, 2023

Primary completion

Feb 22, 2024

Study completion Feb 22, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Female only, from 50 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This will be a Phase I, multicentre, single-dose, non-randomized, open-label, parallel-group study to examine the PK, safety, and tolerability of camizestrant 75 mg in post-menopausal female participants with moderate or severe hepatic impairment compared with post-menopausal female participants with normal hepatic function. Participants will be enrolled within the following groups based on their CP classification score as determined at screening: * Group 1: Matched-control healthy participants with normal hepatic function. * Group 2: Participants with moderate hepatic impairment (CP Class B, score of 7 to 9). * Group 3: Participants with severe hepatic impairment (CP Class C, score of 10 to 15).

Conditions

  • Hepatic Impairment

Interventions

  • CamizestrantDrug

    Camizestrant 75 mg tablets. Experimental drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parameters CmaxTime frame: 5 days
  2. PK parameters tmaxTime frame: 5 days
  3. PK parameters AUClast,Time frame: 5 days
  4. PK parameters AUCinf.;Time frame: 5 days
  5. PK parameters tlastTime frame: 5 days
  6. PK parameters t1/2λzTime frame: 5 days
  7. PK parameters CL/FTime frame: 5 days
  8. PK parameters Vz/F.Time frame: 5 days

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    San Antonio, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Bratislava, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.